• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Q BioMed wins federal contract for bone cancer drug

March 2, 2021 By Sean Whooley

Q-BiomedQ BioMed (OTCQB:QBIO) announced today that it signed an agreement for its Strontium89 drug to be included on the Federal Supply Schedule (FSS).

New York-based Q BioMed’s agreement with the U.S. government provides U.S. veterans and other federal government agencies and eligible patients access to Strontium89, a treatment for metastatic bone pain related to common cancers, according to a news release.

The final FSS contract was made effective March 1, 2021, and consists of a five-year term as it extends access to the drug over 9 million VA beneficiaries and others within the federal system.

Strontium89 is administered once every three months via injection. In a pivotal trial of the drug, as many as 79% of patients experienced pain relief with Strontium89, while twice as many patients treated with it had no pain for three months compared to the placebo group. Additionally, new pain sites were less frequent in patients treated with Strontium89.

Q BioMed plans to commercially serve the U.S. Dept. of Veterans Affairs and the Defense Dept. with a VA sales force, formulary and market access, medical education and marketing. The company plans to begin its commercialization efforts in this area this month while building throughout 2021.

“Q BioMed is very encouraged by this important milestone. This agreement further extends the commercial reach of Strontium89 to eligible adult patients suffering pain from metastatic bone cancer in the VA and other federal agencies,” Q BioMed CEO Denis Corin said in the release. “Q BioMed is committed to helping those who serve and have served their country and their families. It is our hope that, through this agreement, we can make a positive impact on the lives of veterans affected by cancer.”

Filed Under: Business/Financial News, Contract Services, Drug-Device Combinations, Featured, Oncology, Pain Management, Pharmaceuticals Tagged With: Q BioMed, qbiomed

IN CASE YOU MISSED IT

  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care
  • Insulet up on Q2 sales beat, raised full-year guidance
  • Aptar acquires Orbital dry powder inhaler license
  • Tandem sinks on Q2 misses, slashed sales guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS